Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomas.
A phase II study of diglycoaldehyde was conducted in 42 patients with malignant melanoma and soft tissue sarcoma. All patients received diglycoaldehyde at a dose of 2 g/m2 iv over 6 hours daily for 3 days. This was repeated every 28 days. Major toxic effects included phlebitis and azotemia, requiring dialysis in one patient. Of the 42 patients, 38 were evaluable for response. One objective response occurred in a patient with malignant melanoma. Diglycoaldehyde at this dose and schedule appears to have no role in the management of malignant melanoma or soft tissue sarcoma.
D000328:Adult; D000368:Aged; D000447:Aldehydes / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007288:Inosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010689:Phlebitis / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014511:Uremia / Q000139:chemically induced
D000447:Aldehydes; C007390:inosine dialdehyde; D007288:Inosine